BIOSERGEN Aktie

 

At the annual general meeting in Biosergen AB (publ) (the “Company”) held today, June 11, 2025, the below resolutions were adopted. All resolutions were adopted in accordance with the presented proposals, which are described in detail in the notice to the annual general meeting available on the Company's website, www.biosergen.net. Resolution on adoption of accounts and allocation of the Company's profits The annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The...

May 21, 2025: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for first quarter 2025. The interim report is available as an attached document and on the company website (www.biosergen.net) BSG005 Demonstrates Therapeutic Effect in High-Risk Patients: Cohort 2 Completed 2025 will be the year we focus on expanding the clinical path for BSG005 beyond India—by preparing for FDA pre-IND meeting and establishing a future-proof production setup for BSG005—while also progressing toward Phase 2 planning in India. These activities are already in motion, driven by the...

Stockholm, Sweden – May 9, 2025 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announces  the proposal of electing Dr. Marco Taglietti, M.D., as a new member of the Board of Directors ahead of the upcoming Annual General Meeting. The proposal is made in light of the Company's continued promising clinical development of its antifungal drug candidate, BSG005, which is currently being investigated in a proof-of-concept trial as a rescue therapy for patients who have failed previous standard-...

The shareholders of Biosergen AB, Reg. No. 559304-1295, (the “Company”) are invited to attend the annual general meeting to be held on Wednesday June 11, 2025, at Fogdevreten 2A, SE-171 65 Solna, at 11:00. Right to participate and notice of participation Shareholders wishing to participate in the annual general meeting must: · be listed in the Company's share register kept by Euroclear Sweden AB as of Monday June 2, 2025; and · have given a notice of their intent to participate to the Company no later than on Wednesday June 4, 2025 by post to Advokatfirman Hammarskiöld & Co, Att:...

Research shows that climate change is driving the rapid spread of Aspergillus, a mold causing deadly infections. Rising temperatures, extreme weather, and elevated CO2 levels create ideal conditions for fungal proliferation, threatening vulnerable populations worldwide. To address this, Biosergen is developing BSG005, a novel antifungal with potent, broad-spectrum efficacy and a strong safety profile. Read the article at biostock.se: https://www.biostock.se/en/2025/05/biosergen-takes-aim-at-climate-driven-fungal-infections/ This is a press release from BioStock - Connecting Innovation &...

As fungal infections continue to be recognized as a growing global health problem, Biosergen is sharpening its focus. The company's recently published annual report highlights the clinical progress made in 2024 and its priorities in addressing an area with significant unmet medical needs. We contacted CEO Tine Olesen for a comment. Read the interview at biostock.se: https://www.biostock.se/en/2025/05/biosergens-ceo-on-the-latest-advancements/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/...

April 30, 2025: Biosergen AB (“Biosergen” or the “Company”) hereby announces that the 2022 annual report is available on the company website www.biosergen.net (https://www.biosergen.net/investor-relations#Financial%20Reports)...

Biosergen is charging into 2025 with momentum, building on a transformative 2024 that showcased the life-saving potential of its antifungal drug candidate, BSG005. As the biotech company continues its mission to combat the global crisis of life-threatening fungal infections, it is focused on key strategic priorities for the year ahead expanding clinical trials, accelerating development, and strengthening its global presence. Read the article at biostock.se: https://www.biostock.se/en/2025/03/biosergen-scales-up-for-future-wins/ This is a press release from BioStock - Connecting...

March 5, 2025: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for fourth quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net 2025: STRENGTHENING BIOSERGEN'S POSITION FOR GLOBAL TRIALS 2025 will be the year we expect to initiate substantial discussions with the U.S. FDA on securing an Investigational New Drug (IND) application for BSG005—an essential step toward conducting clinical trials in the U.S. We plan to enter these discussions with strong clinical data from our ongoing trial in India and...

December 20, 2024 – Stockholm, Sweden – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, announces that the independent Data Safety Review Board that is monitoring the safety and efficacy of the current clinical study, has agreed to allow investigators to exceed the previously established maximum dose of 1.5 mg/kg/day in the ongoing second cohort of its clinical trial for BSG005. This decision was made following a request from the Principal Investigator, supported by compelling preliminary data, reflecting the...

The exercise period for Biosergen AB (”Biosergen” or the "Company") warrants of series TO3 (the "Warrants") was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors has today, on December 5, 2024, relying on the authorization from the Annual General Meeting on June 14, 2024, resolved on a directed issue of 734,963 shares to such underwriters in the warrant program who have chosen to receive underwriting compensation in the form of newly issued shares in the Company (the "Compensation...

Biosergen AB (”Biosergen” or the "Company") announces today the outcome of the exercise of warrants of series TO3, which were issued in connection with a rights issue in the Company during the first quarter 2024. In total, 91,701,328 warrants of series TO3 were exercised, corresponding to 100.0 percent of the total number of outstanding warrants of series TO3, for subscription of 91,701,328 shares at an exercise price of SEK 0.49 per share. Biosergen will receive approximately SEK 44.9 million before issuing costs through the exercise of the warrants of series TO3. Upon the exercise period...

The exercise period for Biosergen AB (”Biosergen” or the "Company") warrants of series TO3 (the "Warrants") was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors has today, on December 3, 2024, relying on the authorization from the Annual General Meeting on June 14, 2024, decided on a directed share issue of 6,348,670 shares (the "Directed Issue") to a number of investors ("the Underwriters"). The subscription price in the Directed Issue is SEK 0.49, which corresponds to the...

November 26, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, is pleased to announce that the first two patients in the second cohort of its ongoing proof-of-concept clinical trial for BSG005 has successfully begun treatment with BSG005. The patients are suffering from a severe infection caused by Aspergillus and Mucor Mycosis respectively. These two patients represent challenging cases where current antifungal treatments have proven ineffective due to resistance and renal impairment. “It is exciting to...

Today, November 26, 2024, is the last day of trading with the warrants of series TO3 (the “Warrants”)in Biosergen AB (”Biosergen” or the "Company"). The exercise period for the warrants of series TO3 runs up until November 29, 2024. One (1) warrant of series TO3 entitles the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO3 is set to SEK 0.49 per share. If all the warrants of series TO3 are exercised, the Company will receive approximately SEK 44.9 million before issuing costs. For the Warrants not to expire without value, it...

November 21, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, is pleased to announce the release of a fireside-chat-style video interview during the World Antimicrobial Resistance Awareness Week (WAAW). The video features the company's CEO, Tine Olesen, in conversation with Dr. Pawan Kumar Singh, Principal Investigator of Biosergen's ongoing proof-of-concept trial for BSG005. The video is now available on the company's website: https://www.biosergen.net/investor-relations#Events,%20Presentations,%20Media “I...

Biosergen AB (”Biosergen” or the "Company") has received subscription commitments and top underwriting commitments totaling approximately SEK 44.9 million, corresponding to approximately 100 percent of the issue proceeds that the Company could raise through the exercise of warrants of series TO3 (the "Warrants"). The subscription commitments amount to approximately SEK 29.9 million, corresponding to 66.5 percent of the Warrants, and have been provided by Östersjöstiftelsen, CEO Tine Kold Olesen, CFO Niels Laursen, CMO Peder M. Andersen, and several major warrant holders. The top underwriting...

Biosergen AB (”Biosergen” or the "Company") completed a rights issue during the first quarter of 2024, consisting of shares and warrants of series TO3. The exercise price for the warrants of series TO3 corresponds to 70 percent of the volume-weighted average price in the Company's share on Nasdaq First North Growth Market during the measurement period, which ran from and including November 4, 2024, up to and including November 15, 2024, however not higher than SEK 0.50 and not less than SEK 0.30. During the measurement period, the volume-weighted average price in the Company's share was...

So far, the majority of patients involved in Biosergen's proof-of-concept study for life-threatening fungal infections have been able to leave the hospital. This suggests the potential effect of BSG005 even at low doses. Moreover, the subscription period for the company's TO3 warrants is approaching, which will take place between November 18 and 29. Watch the interview with CEO Tine Olesen at biostock.se: https://www.biostock.se/en/2024/11/biosergen-discusses-positive-results-in-patients-with-deadly-fungal-infections/ This is a press release from BioStock - Connecting Innovation &...

Friday November 8, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the third quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net)     BIOSERGEN HAS COMPLETED FIRST PATIENT COHORT The most significant recent result for Biosergen is the successful completion of the treatment of the first cohort of patients in our clinical trial for BSG005. The early data are remarkable, with some patients achieving complete recovery at a low dose of BSG005, while others experienced significant...